Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemastine fumarate for cognitive impairment in alcohol use disorder
jRCTs041220020Completed
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of clemastine in alcohol use disorder (AUD), alcohol dependence and cognitive disorder (CD). Primary endpoint: All-cause discontinuation rate. Started Jun 2022; status: completed.
02
Drugs
clemastine
03
Conditions
alcohol use disorder (AUD)alcohol dependencecognitive disorder (CD)
Beyond the preview
Go deeper on jRCTs041220020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220020.